LLY, NVO Stocks Led May’s GLP-1 Rally — But This Smaller ‘Differentiated Player’ Got A Bold 160% Upside Call
Eli Lilly (LLY) and Novo Nordisk (NVO) led gains in obesity-drug stocks in May. Viking Therapeutics (VKTX) received a 'Buy' rating and $83 price target from Truist, citing its obesity pipeline and 162% upside potential. LLY raised its 2026 sales outlook after Q1 revenue rose 56% to $19.8B. NVO defended its obesity strategy, focusing on broader health outcomes and oral drug advantages.
How this was made
The 30-second read
Why it matters
Analyst upgrade on VKTX provides a fresh catalyst, while LLY and NVO continue to benefit from expanding GLP‑1 markets.
Market read
Obesity‑drug sector momentum drives notable price moves; new coverage on VKTX adds a high‑upside trade idea.
What to watch
Potential regulatory scrutiny of GLP‑1 pricing and reimbursement could limit growth despite strong demand.
Background
The article reviews May performance of major obesity‑drug players and introduces new analyst coverage for Viking Therapeutics.
Ticker impact
LLY shares rose ~25% in May as the company expanded its GLP‑1 obesity‑drug franchise and crossed the $1 trillion market‑cap milestone.
Continued upside if obesity‑drug demand stays robust; watch for earnings guidance.
Recent sales surge and market‑cap milestone suggest sustained buying pressure, but macro‑risk remains.
NVO gained 8% in May as its oral Wegovy rollout accelerated and the company announced price cuts for Wegovy and Ozempic.
Potential further upside if oral adoption accelerates; monitor pricing impact on margins.
Oral product traction and price cuts could expand market share, but competition remains intense.
Truist initiated coverage of Viking Therapeutics with a Buy rating and an $83 price target, implying a 162% upside based on its dual GLP‑1/GIP candidate VK2735.
Expect significant upside if clinical data continue to support efficacy claims; volatility likely.
New coverage and a large price‑target increase provide a clear actionable signal for traders.
Market effects
Highlights continued investor enthusiasm for GLP‑1 obesity therapeutics and may lift related biotech stocks.
U.S. biotech sector sees inflows; European peers may experience relative outflows.
Obesity‑drug pipeline progress is a global health trend influencing pharma valuations worldwide.
Counterpoint
The sector may be over‑priced; efficacy gains could plateau and safety concerns may emerge, tempering upside.
Key entities
- companyEli Lilly
Leader in GLP‑1 obesity drugs, stock up ~25% in May.
- companyNovo Nordisk
Second‑largest obesity‑drug player, stock up ~8% in May.
- companyViking Therapeutics
Smaller biotech receiving a new Buy rating with 162% upside target.
